Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia

(2010) E. I. Zimmerman et al.   MOLECULAR PHARMACOLOGY

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Proteomic and Genetic Approaches Identify Syk as an AML Target

(2009) Cynthia K. Hahn et al.   CANCER CELL

Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth Arrest

(2009) O. Bailet et al.   CANCER RESEARCH

Quantitative Phosphoproteomics Reveals a Cluster of Tyrosine Kinases That Mediates Src Invasive Activity in Advanced Colon Carcinoma Cells

(2009) C. Leroy et al.   CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

(2008) J. Wu et al.   BLOOD

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

(2008) Y.-X. Zhang et al.   CANCER RESEARCH

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute